What Atea Pharmaceuticals, Inc. told the SEC could break it.

Atea relies on a single China-based supplier for ruzasvir's active pharmaceutical ingredient and sources all regulatory starting materials for both ruzasvir and bemnifosbuvir from China, with no long-term supply agreements and no alternative sources — a concentrated, fragile supply chain.

“For ruzasvir, we have a sole supplier located in China for our active pharmaceutical ingredient, and for both ruzasvir and bemnifosbuvir, all suppliers of the regulatory starting 84 materials for the respective manufacturing processes are located in China. We do not have long-term supply agreements with any of our component suppliers.”

Atea has never generated product revenue, posted a $158.3M net loss in 2025 and a $522.6M accumulated deficit (with $301.8M cash), depending on its HCV program's success and equity financing (a $200M Jefferies ATM) to continue.

“As of December 31, 2025, we had an accumulated deficit of $522.6 million. We have not commercialized any products and have never generated any revenue from product sales.”

Because Atea's API and starting materials come from China, U.S. tariffs and shifting trade policy (some 2025 tariffs were challenged but may be reimposed) could raise costs and force operational changes.

“tariffs enacted by the US federal government in 2025 have been subject to successful legal challenge, but it remains unclear whether and to whom those tariffs may be refunded, and the US federal government may attempt to impose new or similar tariffs under alternative statutory mechanisms.”